報價延遲最少15分鐘:2025/11/17 05:46 EST
盤前時段
|
||||
|
0.9048 
|
|
|
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.9048
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-2.60/-0.75
|
|
企業價值
94.76M
|
| 資產負債 |
|
每股賬面淨值
-1.03
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
62.04M
|
|
每股收益
0.67
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
報價延遲最少15分鐘：2025/11/17 05:46 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancerand autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others. |
